Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Dementia

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

Role of Neurotransmitters in Memory

Role of Neurotransmitters in Memory

Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Towards pharmacological prevention of Alzheimer disease.

Nature reviews. Neurology·2025

Same author

The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

Interpreting the evidence on gantenerumab for dominantly inherited Alzheimer's disease - Authors' reply.

The Lancet. Neurology·2025

Same author

Ubiquitin-proteasome system in the different stages of dominantly inherited Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.

The Lancet. Neurology·2025

Same author

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial.

medRxiv : the preprint server for health sciences·2025

Search research articles

Related Experiment Video

Updated: Sep 20, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

Alzheimer Disease.

Continuum (Minneapolis, Minn.)

|June 9, 2022

Summary

Early Alzheimer disease (AD) diagnosis is improving with new fluid and imaging biomarkers. Understanding risk factors and targeting amyloid are key for future AD therapies and slowing cognitive decline.

Area of Science:

Neurology
Biomarker Discovery
Geriatric Medicine

Background:

Alzheimer disease (AD) is the leading cause of dementia in adults.
Understanding AD risk factors, symptoms, and treatments is crucial.

Purpose of the Study:

To review recent advancements in AD diagnostics and therapeutics.
To highlight the importance of early diagnosis and risk factor management.

Main Methods:

Analysis of fluid biomarkers (CSF, plasma) for tau and amyloid.
Utilizing positron emission tomography (PET) imaging for AD pathology.
Review of recent clinical trials for amyloid-lowering drugs.

Main Results:

Fluid and imaging biomarkers enable precise, earlier AD diagnosis.

More Related Videos

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

Related Experiment Videos

Last Updated: Sep 20, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

Biomarkers detect AD pathology (tau, amyloid) across the disease spectrum.

Addressing comorbidities is vital for preventing cognitive decline.

Conclusions:

Biomarker advancements improve AD understanding as a chronic condition.
Early diagnosis and risk factor management are essential for patient care.
Future therapies will likely require targeting multiple pathways for disease modification.